Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer

This publication has 19 references indexed in Scilit:

• Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
  British Journal of Cancer, 1999
• Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
  Journal of Clinical Oncology, 1998
• Relationship of Mitotic Arrest and Apoptosis to Antitumor Effect of Paclitaxel
  JNCI Journal of the National Cancer Institute, 1996
• In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product
  British Journal of Cancer, 1996
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
  Journal of Clinical Oncology, 1996
• A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines
  European Journal Of Cancer, 1996
• The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
  Gene, 1995
• Humanization of an anti-p185HER2 antibody for human cancer therapy.
  Proceedings of the National Academy of Sciences, 1992
• Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
  JNCI Journal of the National Cancer Institute, 1991
• Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene
  Science, 1985